{"id":"lucanthone","rwe":[{"pmid":"41395284","year":"2025","title":"Lucanthone inhibits the proliferation of lung cancer cells by suppressing the cuproptosis-related pathway.","finding":"","journal":"American journal of cancer research","studyType":"Clinical Study"},{"pmid":"40684232","year":"2025","title":"Targeting autophagy and plasminogen activator inhibitor-1 increases survival and remodels the tumor microenvironment in glioblastoma.","finding":"","journal":"Journal of experimental & clinical cancer research : CR","studyType":"Clinical Study"},{"pmid":"40408617","year":"2025","title":"Bioinformatics and system biology approach to discover the common pathogenetic processes between COVID-19 and chronic hepatitis B.","finding":"","journal":"PloS one","studyType":"Clinical Study"},{"pmid":"40406126","year":"2025","title":"Identification and validation of shared biomarkers and drug repurposing in psoriasis and Crohn's disease: integrating bioinformatics, machine learning, and experimental approaches.","finding":"","journal":"Frontiers in immunology","studyType":"Clinical Study"},{"pmid":"40166636","year":"2025","title":"Identification and validation of biomarkers associated with mitochondrial dysfunction and ferroptosis in rat spinal cord injury.","finding":"","journal":"Frontiers in neurology","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"DNA-(apurinic or apyrimidinic site) lyase","category":"target"},{"label":"APEX1","category":"gene"},{"label":"Active","category":"status"},{"label":"Anthelmintics","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antiparasitic Agents","category":"pharmacology"},{"label":"Antiplatyhelmintic Agents","category":"pharmacology"},{"label":"Schistosomicides","category":"pharmacology"}],"phase":"discontinued","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["lucanthone","lucanthone hydrochloride","lucanthone HCl"],"offLabel":[],"synonyms":["lucanthone","lucanthone hydrochloride","lucanthone HCl"],"timeline":[],"aiSummary":"LUCANTHONE is a small molecule modality targeting DNA-(apurinic or apyrimidinic site) lyase, but its exact mechanism and clinical status are unclear. As a pharmaceutical professional, it is essential to note that LUCANTHONE's development history, commercial status, and approved indications are not publicly available. Further research is necessary to understand its potential therapeutic applications and safety profile. The lack of information on its pharmacokinetic properties, such as half-life and bioavailability, also raises concerns about its clinical use. Overall, LUCANTHONE remains a mysterious entity in the pharmaceutical landscape.","approvals":[],"ecosystem":[],"mechanism":{"target":"DNA-(apurinic or apyrimidinic site) lyase","targets":[{"gene":"APEX1","source":"DrugCentral","target":"DNA-(apurinic or apyrimidinic site) lyase","protein":"DNA-(apurinic or apyrimidinic site) lyase"}],"modality":"Small Molecule","explanation":"Think of DNA like a long, fragile ladder. When the ladder gets damaged, DNA-(apurinic or apyrimidinic site) lyase helps fix it. LUCANTHONE blocks this enzyme, which can be beneficial in certain types of cancer or other diseases where DNA damage is a problem.","oneSentence":"LUCANTHONE works by inhibiting DNA-(apurinic or apyrimidinic site) lyase, an enzyme involved in DNA repair.","technicalDetail":"LUCANTHONE specifically targets the AP endonuclease activity of DNA-(apurinic or apyrimidinic site) lyase, a crucial step in the base excision repair pathway."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1616","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=LUCANTHONE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LUCANTHONE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:25:48.771285","biosimilars":[],"competitors":[{"drugName":"mitoxantrone","drugSlug":"mitoxantrone","fdaApproval":"1987-12-23","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"lucanthone","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"mitoxantrone","brandName":"mitoxantrone","genericName":"mitoxantrone","approvalYear":"1987","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT01587144","phase":"PHASE2","title":"Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)","status":"TERMINATED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2012-06-19","conditions":["Glioblastoma Multiforme"],"enrollment":18,"completionDate":"2013-04-15"},{"nctId":"NCT02014545","phase":"PHASE2","title":"Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2016-01","conditions":["Brain Metastases","Non-small Cell Lung Cancer"],"enrollment":0,"completionDate":"2017-11-29"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NDDF":"002982","UNII":"FC6D57000M","CHEBI":"CHEBI:51052","INN_ID":"337","UMLSCUI":"C0024071","ChEMBL_ID":"CHEMBL279014","KEGG_DRUG":"D04791","DRUGBANK_ID":"DB04967","PUBCHEM_CID":"10180","SNOMEDCT_US":"68310009","SECONDARY_CAS_RN":"548-57-2","MESH_DESCRIPTOR_UI":"D008154"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":148,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[{"date":"2025","pmid":"41395284","title":"Lucanthone inhibits the proliferation of lung cancer cells by suppressing the cuproptosis-related pathway.","journal":"American journal of cancer research"},{"date":"2025 Jul 19","pmid":"40684232","title":"Targeting autophagy and plasminogen activator inhibitor-1 increases survival and remodels the tumor microenvironment in glioblastoma.","journal":"Journal of experimental & clinical cancer research : CR"},{"date":"2025","pmid":"40408617","title":"Bioinformatics and system biology approach to discover the common pathogenetic processes between COVID-19 and chronic hepatitis B.","journal":"PloS one"},{"date":"2025","pmid":"40406126","title":"Identification and validation of shared biomarkers and drug repurposing in psoriasis and Crohn's disease: integrating bioinformatics, machine learning, and experimental approaches.","journal":"Frontiers in immunology"},{"date":"2025","pmid":"40166636","title":"Identification and validation of biomarkers associated with mitochondrial dysfunction and ferroptosis in rat spinal cord injury.","journal":"Frontiers in neurology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"discontinued","brandName":"LUCANTHONE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}